Surgical Science Sweden Resultados de beneficios anteriores
Pasado controles de criterios 3/6
Surgical Science Sweden ha aumentado sus beneficios a una tasa media anual de 66.3%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 5% anual. Los ingresos han ido creciendo a una tasa media de 54% al año. La rentabilidad financiera de Surgical Science Sweden es de 5.4%, y sus márgenes netos son de 26.5%.
Información clave
66.3%
Tasa de crecimiento de los beneficios
61.7%
Tasa de crecimiento del BPA
| Crecimiento de la industria Medical Equipment | 6.2% |
| Tasa de crecimiento de los ingresos | 54.0% |
| Rentabilidad financiera | 5.4% |
| Margen neto | 26.5% |
| Próxima actualización de resultados | 15 May 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21
Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09
Surgical Science Sweden AB (publ)'s (STO:SUS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 01What Does Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Indicate?
Dec 14Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Nov 26Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Surgical Science Sweden. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 23 | 883 | 234 | 240 | 182 |
| 30 Sep 23 | 906 | 253 | 230 | 182 |
| 30 Jun 23 | 901 | 234 | 222 | 185 |
| 31 Mar 23 | 872 | 221 | 215 | 179 |
| 31 Dec 22 | 803 | 188 | 202 | 173 |
| 30 Sep 22 | 750 | 138 | 200 | 159 |
| 30 Jun 22 | 640 | 124 | 176 | 130 |
| 31 Mar 22 | 489 | 101 | 146 | 97 |
| 31 Dec 21 | 367 | 86 | 117 | 66 |
| 30 Sep 21 | 209 | 30 | 76 | 37 |
| 30 Jun 21 | 138 | 21 | 60 | 26 |
| 31 Mar 21 | 122 | 18 | 53 | 20 |
| 31 Dec 20 | 105 | 16 | 50 | 17 |
| 30 Sep 20 | 104 | 14 | 51 | 18 |
| 30 Jun 20 | 112 | 19 | 54 | 19 |
| 31 Mar 20 | 107 | 17 | 52 | 19 |
| 31 Dec 19 | 102 | 13 | 51 | 17 |
| 30 Sep 19 | 88 | 6 | 49 | 15 |
| 30 Jun 19 | 70 | -5 | 43 | 13 |
| 31 Mar 19 | 68 | -5 | 43 | 13 |
| 31 Dec 18 | 66 | -5 | 39 | 14 |
| 30 Sep 18 | 60 | -3 | 38 | 10 |
| 30 Jun 18 | 57 | -6 | 37 | 7 |
| 31 Mar 18 | 56 | -7 | 34 | 4 |
| 31 Dec 17 | 57 | -3 | 31 | 0 |
| 30 Sep 17 | 65 | 4 | 30 | 0 |
| 30 Jun 17 | 60 | 3 | 27 | 0 |
| 31 Mar 17 | 59 | 4 | 27 | 0 |
| 31 Dec 16 | 58 | 3 | 29 | 0 |
| 31 Dec 15 | 52 | 2 | 24 | 0 |
| 31 Dec 14 | 41 | -3 | 21 | 0 |
Ingresos de calidad: SUS tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (26.5%) de SUS son superiores a los del año pasado (23.4%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: SUS ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 66.3% al año.
Acelerando crecimiento: El crecimiento de los beneficios de SUS en el último año (24.5%) está por debajo de su media de 5 años (66.3% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de SUS en el último año (24.5%) no superó al de la industria Medical Equipment 25.4%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de SUS (5.4%) se considera baja.